About: Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine
Creator	Org, Wakim, Linda Valkenburg, Sophie Van De Sandt, Carolien Wong, Sook Clemens, E Wong@stjude, Sook-San
Source	Medline; PMC
abstract	Next-generation vaccines that utilize T cells could potentially overcome the limitations of current influenza vaccines that rely on antibodies to provide narrow subtype-specific protection and are prone to antigenic mismatch with circulating strains. Evidence from animal models shows that T cells can provide heterosubtypic protection and are crucial for immune control of influenza virus infections. This has provided hope for the design of a universal vaccine able to prime against diverse influenza virus strains and subtypes. However, multiple hurdles exist for the realisation of a universal T cell vaccine. Overall primary concerns are: extrapolating human clinical studies, seeding durable effective T cell resident memory (Trm), population human leucocyte antigen (HLA) coverage, and the potential for T cell-mediated immune escape. Further comprehensive human clinical data is needed during natural infection to validate the protective role T cells play during infection in the absence of antibodies. Furthermore, fundamental questions still exist regarding the site, longevity and duration, quantity, and phenotype of T cells needed for optimal protection. Standardised experimental methods, and eventually simplified commercial assays, to assess peripheral influenza-specific T cell responses are needed for larger-scale clinical studies of T cells as a correlate of protection against influenza infection. The design and implementation of a T cell-inducing vaccine will require a consensus on the level of protection acceptable in the community, which may not provide sterilizing immunity but could protect the individual from severe disease, reduce the length of infection, and potentially reduce transmission in the community. Therefore, increasing the standard of care potentially offered by T cell vaccines should be considered in the context of pandemic preparedness and zoonotic infections, and in combination with improved antibody vaccine targeting methods. Current pandemic vaccine preparedness measures and ongoing clinical trials under-utilise T cell-inducing vaccines, reflecting the myriad questions that remain about how, when, where, and which T cells are needed to fight influenza virus infection. This review aims to bring together basic fundamentals of T cell biology with human clinical data, which need to be considered for the implementation of a universal vaccine against influenza that harnesses the power of T cells.
has issue date	2018-03-26(xsd:dateTime)
bibo:doi	10.3390/vaccines6020018
bibo:pmid	29587436
has license	cc-by
sha1sum (hex)	aef8022f38dee0b0eadc00eb8a955384b87f3626
schema:url	https://doi.org/10.3390/vaccines6020018
resource representing a document's title	Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine
has PubMed Central identifier	PMC6027237
has PubMed identifier	29587436
schema:publication	Vaccines (Basel)
resource representing a document's body	covid:aef8022f38dee0b0eadc00eb8a955384b87f3626#body_text
is schema:about of	named entity 'remain' named entity 'infection' named entity 'T cell' named entity 'exist' named entity 'zoonotic' named entity 'immune' named entity 'reduce' named entity 'human' named entity 'Hope' named entity 'Vaccine' named entity 'LONGEVITY' named entity 'EVIDENCE' covid:arg/aef8022f38dee0b0eadc00eb8a955384b87f3626 named entity 'UNIVERSAL' named entity 'ZOONOTIC INFECTIONS' named entity 'MEMORY' named entity 'SPECIFIC' named entity 'MULTIPLE' named entity 'INFLUENZA VACCINE' named entity 'PERIPHERAL' named entity 'RESPONSES' named entity 'SCALE' named entity 'SEVERE DISEASE' named entity 'IMPROVED' named entity 'TO PROVIDE' named entity 'ESCAPE' named entity 'EXPERIMENTAL METHODS' named entity 'AIMS' named entity 'CLINICAL STUDIES' named entity 'FIGHT' named entity 'COVERAGE' named entity 'CURRENT' named entity 'ASSESS' named entity 'POWER' named entity 'BUT' named entity 'PROTECTION' named entity 'LIMITATIONS' named entity 'EXIST' named entity 'OVERALL' named entity 'BASIC' named entity 'INFLUENZA VIRUS' named entity 'INCREASING' named entity 'PHENOTYPE' named entity 'VACCINES' named entity 'WHERE' named entity 'EFFECTIVE' named entity 'HOPE' named entity 'GENERATION' named entity 'CLINICAL DATA' named entity 'PLAY' named entity 'UNIVERSAL' named entity 'ABSENCE OF' named entity 'PRONE' named entity 'T CELLS' named entity 'POTENTIAL' named entity 'VACCINES' named entity 'T CELLS' named entity 'POWER' named entity 'MEASURES' named entity 'NATURAL INFECTION' named entity 'RESIDENT' named entity 'INDIVIDUAL' named entity 'PANDEMIC' named entity 'ONGOING' named entity 'TARGETING' named entity 'POPULATION' named entity 'HUMAN' named entity 'INFECTIONS' named entity 'COMPREHENSIVE' named entity 'INFLUENZA INFECTION' named entity 'IMPLEMENTATION' named entity 'INFECTION' named entity 'PREPAREDNESS' named entity 'STANDARD OF CARE' named entity 'IMMUNE CONTROL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software